Objectives: Androgen deprivation therapy is the standard treatment for metastatic prosta-te cancer. Although the current treatment met-hods the disease becomes hormone resistant after a while. In our study, patients diagnosed with metastatic prostate cancer, we investiga-ted the effects of modern treatment methods in terms of the clinical course and survival.
Materials and Methods: Between 2005-2012, 118 patients followed at our outpatient clinic with diagnosis of metastatic prostate can-cer were retrospectively analyzed. Clinical cha-racteristics, hormonal treatment modalities of patients, disease and treatment-related compli-cations, disease progression and survival time were recorded.
Results: The mean age of the patients at di-agnosis was 69.4 (53-87) years, mean PSA le-vel before biopsy was 255.1 (20-2000) ng / ml and the mean Gleason score was 8.1 (7-10) . The mean hormone resistance development time in patients receiving hormonal therapy was 22.8 ± 10.9 months. The mean survival of patients with hormone resistant prostate cancer (HRPC) was 13.7 (3-19) months. The mean time between the diagnose and death in metastatic prostate can-cer patients was 36.6 ± 14.8 months. There was no statistical difference between neither mo-notherapy group (LHRH therapy or orchidec-tomy) and maximal androgen deprivation the-rapy group (orchidectomy or LHRH therapy with antiandrogen drugs) (35.7±12 months – 37.2±16.4 months, P=0.59) nor the intermittent hormonal therapy patients and continuous hor-monal therapy given group (38±12.1 months - 35.5±16.7 months, P=0.35) in terms of mean survival rates. In patients receiving chemotherapy, the median sur-vival was 7.4 months.
Conclusion: Metastatic prostate cancer, when considering the disease itself as well as the side effects of treatment is a disease that requires careful treatment with the supportive therapy. Although metastatic prostate cancer is a hormone-sensitive tumor, intermit-tent or continuous hormonal therapy, MAB or monotherapy any of them are given, there are no differences in terms of survival.
Key Words: Metastatic prostate cancer, hormonal therapy, sur-vival
Abstract
Objectives: Androgen deprivation therapy is the standard treatment for metastatic prosta-te cancer. Although the current treatment met-hods the disease becomes hormone resistant after a while. In our study, patients diagnosed with metastatic prostate cancer, we investiga-ted the effects of modern treatment methods in terms of the clinical course and survival.
Materials and Methods: Between 2005-2012, 118 patients followed at our outpatient clinic with diagnosis of metastatic prostate can-cer were retrospectively analyzed. Clinical cha-racteristics, hormonal treatment modalities of patients, disease and treatment-related compli-cations, disease progression and survival time were recorded.
Results: The mean age of the patients at di-agnosis was 69.4 (53-87) years, mean PSA le-vel before biopsy was 255.1 (20-2000) ng / ml and the mean Gleason score was 8.1 (7-10) . The mean hormone resistance development time in patients receiving hormonal therapy was 22.8 ± 10.9 months. The mean survival of patients with hormone resistant prostate cancer (HRPC) was 13.7 (3-19) months. The mean time between the diagnose and death in metastatic prostate can-cer patients was 36.6 ± 14.8 months. There was no statistical difference between neither mo-notherapy group (LHRH therapy or orchidec-tomy) and maximal androgen deprivation the-rapy group (orchidectomy or LHRH therapy with antiandrogen drugs) (35.7±12 months – 37.2±16.4 months, P=0.59) nor the intermittent hormonal therapy patients and continuous hor-monal therapy given group (38±12.1 months - 35.5±16.7 months, P=0.35) in terms of mean survival rates. In patients receiving chemotherapy, the median sur-vival was 7.4 months.
Conclusion: Metastatic prostate cancer, when considering the disease itself as well as the side effects of treatment is a disease that requires careful treatment with the supportive therapy. Although metastatic prostate cancer is a hormone-sensitive tumor, intermit-tent or continuous hormonal therapy, MAB or monotherapy any of them are given, there are no differences in terms of survival.
Key Words: Metastatic prostate cancer, hormonal therapy, sur-vival